DE602005016405D1 - Verbesserung der bildqualität im auge - Google Patents

Verbesserung der bildqualität im auge

Info

Publication number
DE602005016405D1
DE602005016405D1 DE602005016405T DE602005016405T DE602005016405D1 DE 602005016405 D1 DE602005016405 D1 DE 602005016405D1 DE 602005016405 T DE602005016405 T DE 602005016405T DE 602005016405 T DE602005016405 T DE 602005016405T DE 602005016405 D1 DE602005016405 D1 DE 602005016405D1
Authority
DE
Germany
Prior art keywords
picture quality
improving picture
zeaxanthin
quality eye
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005016405T
Other languages
German (de)
English (en)
Inventor
John Barbur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Publication of DE602005016405D1 publication Critical patent/DE602005016405D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Eye Examination Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
DE602005016405T 2004-06-29 2005-06-08 Verbesserung der bildqualität im auge Expired - Lifetime DE602005016405D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04015189 2004-06-29
PCT/EP2005/006168 WO2006002735A1 (en) 2004-06-29 2005-06-08 Improvement of image quality in the eye

Publications (1)

Publication Number Publication Date
DE602005016405D1 true DE602005016405D1 (de) 2009-10-15

Family

ID=35782481

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005016405T Expired - Lifetime DE602005016405D1 (de) 2004-06-29 2005-06-08 Verbesserung der bildqualität im auge

Country Status (9)

Country Link
US (2) US20080045605A1 (enExample)
EP (1) EP1761254B1 (enExample)
JP (1) JP5074184B2 (enExample)
KR (1) KR20070027649A (enExample)
CN (1) CN101094666B (enExample)
AT (1) ATE441406T1 (enExample)
DE (1) DE602005016405D1 (enExample)
ES (1) ES2331083T3 (enExample)
WO (1) WO2006002735A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084687A1 (en) * 2005-02-11 2006-08-17 Dsm Ip Assets B.V. Use of zeaxanthin for the treatment of diseases of the peripheral retina
AT503329A1 (de) * 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218436B1 (en) * 1993-06-28 2001-04-17 The Howard Foundation Pharmaceutically active carotenoids
US5382714A (en) * 1994-03-17 1995-01-17 The Catholic University Of America Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof
US5827652A (en) * 1995-10-31 1998-10-27 Applied Food Biotechnology, Inc. Zeaxanthin formulations for human ingestion
FR2749758B1 (fr) * 1996-06-12 1998-08-07 Oenobiol Sa Lab Composition a activite bronzante et photoprotectrice et ses applications esthetiques
WO1997048388A1 (en) * 1996-06-17 1997-12-24 The Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
US6075058A (en) * 1998-12-12 2000-06-13 Tufts University Compositions for increased bioavailability of carotenoids
US6712466B2 (en) * 2001-10-25 2004-03-30 Ophthonix, Inc. Eyeglass manufacturing method using variable index layer
ES2299687T3 (es) * 2002-01-30 2008-06-01 Dsm Ip Assets B.V. Luteina/zeaxantina para la proteccion contra el encandilamiento.
CN1481804A (zh) * 2002-12-17 2004-03-17 无锡杰西医药科技有限公司 防治白内障、黄斑变性等眼病的配方及其使用方法

Also Published As

Publication number Publication date
CN101094666A (zh) 2007-12-26
JP2008505137A (ja) 2008-02-21
ATE441406T1 (de) 2009-09-15
EP1761254A1 (en) 2007-03-14
US20080045605A1 (en) 2008-02-21
CN101094666B (zh) 2010-09-29
WO2006002735A1 (en) 2006-01-12
KR20070027649A (ko) 2007-03-09
EP1761254B1 (en) 2009-09-02
ES2331083T3 (es) 2009-12-21
US20110172313A1 (en) 2011-07-14
JP5074184B2 (ja) 2012-11-14

Similar Documents

Publication Publication Date Title
ES2955713T3 (es) Agente de mejora de la función visual, y método para mejorar la función visual
Pinto et al. N-acetylcysteine treatment reduces TNF-α levels and myonecrosis in diaphragm muscle of mdx mice
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
WO2012038512A3 (en) Composition comprising sod, lutein and zeaxanthin
IL172613A0 (en) Pan-kir2dl nk-receptor antibodies and their use in diagnostic and therapy
NO20092633L (no) Ernaeringstilskuddsammensetning for behandling av okulare sykdommer
WO2012125830A3 (en) Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control
EA201001283A1 (ru) Комбинация витамина d и 25-гидроксивитамина d3
MY208400A (en) Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof
WO2018169282A3 (ko) Atpif1을 함유하는 당뇨 치료용 약학조성물
DK2111125T3 (da) Flydende formuleringer indeholdende carotinoider
MXPA05005171A (es) Compuestos bi-aromaticos activadores de los receptores de tipo ppar-gama y su uso en composiciones cosmeticas o farmaceuticas.
MY177974A (en) A pharmaceutical composition for prevention of diet induced obesity
EA201201239A1 (ru) Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением
PH12019500949A1 (en) Ror-gamma modulators
MX2007001943A (es) Nuevos compuestos biaromaticos activadores de los receptores del tipo receptor activado del proliferador de peroxisoma (ppar) y su uso en composiciones cosmeticas o farmaceuticas.
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
Musa et al. Nutritional Factors: benefits in glaucoma and ophthalmologic pathologies
EP4566629A3 (en) Use of low volume plasma exchange for the treatment of alzheimer s disease in early and middle stages
Feng et al. Cytoprotective effect of lacritin on human corneal epithelial cells exposed to benzalkonium chloride in vitro
MX2019003725A (es) Glicinato de metformina, composiciones farmaceuticas que comprenden la misma, y metodos de uso de la misma.
WO2015048503A3 (en) N-arylmethyl sulfonamide negative modulators of nr2a
AR092691A1 (es) Composicion farmaceutica que comprende rebamipida
GB201310235D0 (en) Nutraceutical and pharmaceutical composition
DE602005016405D1 (de) Verbesserung der bildqualität im auge

Legal Events

Date Code Title Description
8364 No opposition during term of opposition